HC Wainwright Issues Negative Outlook for ALGS Earnings

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – Equities research analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for Aligos Therapeutics in a research note issued on Tuesday, May 12th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.75) for the quarter, down from their previous forecast of ($0.22). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($6.95) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q3 2026 earnings at ($3.16) EPS, Q4 2026 earnings at ($2.22) EPS, FY2026 earnings at ($8.42) EPS, Q1 2027 earnings at ($1.03) EPS, Q2 2027 earnings at ($1.04) EPS, Q3 2027 earnings at ($1.06) EPS, Q4 2027 earnings at ($0.44) EPS, FY2027 earnings at ($3.56) EPS, FY2028 earnings at ($2.69) EPS, FY2029 earnings at ($2.28) EPS and FY2030 earnings at ($0.82) EPS.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating the consensus estimate of ($2.29) by $0.08. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%.The company had revenue of $2.83 million for the quarter, compared to analyst estimates of $0.25 million.

ALGS has been the topic of several other reports. Westpark Capital assumed coverage on Aligos Therapeutics in a report on Thursday, March 26th. They set a “buy” rating and a $48.00 target price on the stock. Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a report on Thursday, March 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Monday, April 20th. Finally, Wall Street Zen lowered Aligos Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $41.50.

Aligos Therapeutics Price Performance

NASDAQ ALGS opened at $6.67 on Thursday. Aligos Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $13.69. The stock’s 50-day moving average is $7.05 and its two-hundred day moving average is $8.06. The firm has a market cap of $41.29 million, a P/E ratio of -0.77 and a beta of 2.28.

Hedge Funds Weigh In On Aligos Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Rockefeller Capital Management L.P. increased its stake in shares of Aligos Therapeutics by 900.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after purchasing an additional 9,000 shares during the period. XTX Topco Ltd bought a new position in Aligos Therapeutics during the fourth quarter valued at about $215,000. SummitTX Capital L.P. bought a new position in Aligos Therapeutics during the fourth quarter valued at about $1,299,000. Verition Fund Management LLC bought a new position in Aligos Therapeutics during the fourth quarter valued at about $664,000. Finally, Marshall Wace LLP bought a new position in Aligos Therapeutics during the fourth quarter valued at about $2,504,000. 60.43% of the stock is currently owned by institutional investors.

More Aligos Therapeutics News

Here are the key news stories impacting Aligos Therapeutics this week:

• Positive Sentiment: Aligos announced ten abstracts accepted for poster presentations at EASL 2026, showcasing multiple pipeline programs in hepatitis B, HDV, and MASH and potentially increasing investor confidence in its clinical development progress. Article Title
• Neutral Sentiment: HC Wainwright reiterated a Buy rating and $50 price target, but adjusted multiple earnings estimates for 2026-2030, reflecting continued belief in the stock’s long-term potential despite near-term losses.
• Neutral Sentiment: The firm lowered estimates for several quarters and fiscal years, including Q2 2026, Q3 2026, Q4 2026, Q2 2027, Q3 2027, Q4 2027, FY2026, FY2027, FY2028, FY2029, and FY2030, which mainly signals updated modeling rather than a change in the investment thesis.
• Negative Sentiment: Some of the revised estimates were weaker than before, suggesting the path to profitability may be more challenging in the near term and could limit upside if execution does not improve.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.